What we are working on
Across our three businesses, our focus on innovation is driving a broad pipeline – from the development of everyday healthcare products to life-saving medicines and vaccines.
Our Pharmaceuticals R&D organisation is focused on research across four therapy areas – two core areas where we already have strong leadership developing new medicines: Respiratory and HIV/infectious diseases; and two potential areas where we have ongoing development programmes: Oncology and immuno-inflammation.
We also invest significantly in broader early discovery research, incubating areas of science outside our four core therapy areas where we think there is the potential to develop transformational medicines. This currently includes research into neuroscience and global health.
Our Vaccines R&D organisation is developing innovative vaccines which have the potential to help reduce the burden of many communicable diseases. At our three global R&D hubs in Belgium, Italy and the USA we’re researching vaccines against bacterial, viral and parasitic pathogens.
Ninety percent of the vaccines in our pipeline are being developed in partnership with others. We have a long track record of collaborating with governments, healthcare providers, regulators, academic institutions, non-governmental organisations, vaccine producers and other key partners to tackle public health challenges around the world.
Our Consumer Healthcare R&D organisation develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health.
Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. Our pipeline is fueled by five global innovation hubs that bring together our R&D, marketing and consumer insights teams, enabling us to develop innovative products based on the everyday healthcare needs of our consumers.
On 19 December 2018 we announced our agreement with Pfizer to form a new world-leading Consumer Healthcare Joint Venture. Within 3 years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more
Find out more
You, me and 23andMe: discovering new medicines through genetics
Explore how our new collaboration with 23andMe could help unlock the medicines of tomorrow.
In the past 25 years, a steady increase in bacteria immune to antibiotics has become a serious threat to global public health
A new scientific field that could one day result in a novel class of miniaturised, implantable device medicines
Our medicines and vaccines currently in development across three stages: phase I, phase II and phase III